Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools IDH-mutant glioma

IDH-mutant glioma

Programs, trials, and reported response and survival for IDH-mutant glioma.

Data as of 11.07.2026

All studies

Vorasidenib

Vorasidenib Phase 1

Servier · Phase n/r · Status n/r · Enrollment n/r

Registry id n/r

ArmPopulationDoseEstimandComparatorEfficacy
Vorasidenib, non-enhancing gliomarecurrent non-enhancing IDH-mutant glioma (n = 22)Phase 1 dosesSingle armn/robjective response rate: 18%, Phase 1median PFS: 36.8 months, Phase 1